With a market capitalization (market cap) of $1.28B — a measure of how much the company is worth — Cullinan Therapeutics, Inc. is the 2424th most valuable company in Healthcare as of August 19, 2026. Shares trade at $20.84, up +1.21% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts.
Visit websiteAs of August 19, 2026, Cullinan Therapeutics, Inc. (CGEM) is worth $1.28B — this is its market capitalization, the total value of all its outstanding shares.
Cullinan Therapeutics, Inc.’s market cap is $1.28B, which ranks it #2424 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Cullinan Therapeutics, Inc. (CGEM) shares trade at $20.84, up 1.21% on the day, as of August 19, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025